(Q34877613)

English

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Frederick R. Appelbaum

12

object named as

Frederick R Appelbaum

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

7

object named as

Elihu H Estey

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Roland B Walter

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Ted A Gooley

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Brent L Wood

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Filippo Milano

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Min Fang

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Mohamed L Sorror

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Alexander I Salter

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Emily Lansverk

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jason W Chien

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Ajay K Gopal

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

John M Pagel

13

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

31 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1190-1197

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Minimal residual disease quantitation in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Flow cytometric immunophenotyping for hematologic neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

9-color and 10-color flow cytometry in the clinical laboratory

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Hematopoietic cell transplantation in first complete remission versus early relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Cytogenetics in acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

8 July 2018

Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

26 October 2018

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

26 October 2018

Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

26 October 2018

The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

26 October 2018

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

26 October 2018

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083874

26 October 2018

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A risk score for mortality after allogeneic hematopoietic cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring of minimal residual disease in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ten-color immunophenotyping of hematopoietic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282535

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.31.8121

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34877613&oldid=1810099253"